NEW YORK, July 13, 2017 -- The Asia Pacific Fund, Inc. (NYSE:APB) (the “Fund”) announced today that its Annual Meeting of Stockholders will be delayed until October 12, 2017 to allow the Fund’s Board of Directors time to consider strategic options for the Fund. The Fund will reopen the submission period for notice of stockholder proposals intended to be presented at such Annual Meeting for an additional period of ten days.
Any such notice of a stockholder proposal must be received by the Fund’s Secretary at 48 Wall Street, 22nd Floor, New York, New York 10005 by not later than 5:00 p.m., Eastern Time on July 23, 2017. Any notice of proposal received after such date will be considered untimely and the related proposal will be excluded from consideration at the Annual Meeting in accordance with the Fund’s Bylaws. The mere submission of a notice of proposal by a stockholder does not guarantee that such proposal will be considered at the Annual Meeting because certain federal rules and the Fund’s Bylaws must be complied with before a proposal may be presented.
The Asia Pacific Fund, Inc. is a diversified, closed-end management investment company, organized as a Maryland corporation and is registered with the SEC under the Investment Company Act of 1940, as amended.
The investment objective of the Fund is to achieve long-term capital appreciation through investment primarily in equity securities in the Asia Pacific countries (excluding Japan). The Fund is managed by Value Partners Hong Kong Limited.
Past performance is no guarantee of future performance. An investment in the Fund is subject to certain risks, including market risk. In general, shares of closed-end funds often trade at a discount from their net asset value and at the time of sale may be trading on the exchange at a price that is more or less than the original purchase price or the net asset value. An investor should carefully consider the Fund’s investment objective, risks, charges and expenses. Please read a Fund’s disclosure documents before investing.
In addition to historical information, this release contains forward-looking statements, which may concern, among other things, domestic and foreign markets, industry and economic trends and developments and government regulation and their potential impact on the Fund’s investment portfolio. These statements are subject to risks and uncertainties, including the factors set forth in the Fund’s disclosure documents, filed with the SEC, and actual trends, developments and regulations in the future, and their impact on the Fund could be materially different from those projected, anticipated or implied. The Fund has no obligation to update or revise forward-looking statements.
For more information, contact: Pristine Advisers – 1-888-4-ASIA-PAC (1-888-427-4272) or via email at [email protected]


Apple Turns 50: From Garage Startup to AI Crossroads
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



